Dataset: Expression array of peripheral neuro-ectodermal cell lines
To study differentially expressed genes in neuro-ectodermal cell lines MYCN amplification (NMA) is the most important prognostic factor...
To study differentially expressed genes in neuro-ectodermal cell lines MYCN amplification (NMA) is the most important prognostic factor in neuroblastoma (NBL) patients, however 70% of advanced stage NBL are non-NMA and lack known driving oncogenic events. Gene expression profiles (HU133plus2.0 arrays, Affymetrix) of 17 NBL and 5 peripheral neuro-ectodermal cell lines were used to identify potential subgroups of NBL cell lines with a distinct gene signature. One group of non-NMA NBL cell lines was identified with a distinct gene expression profile and characterized by high expression of AXL. AXL is a tyrosine kinase receptor which plays a role in the metastatic process of cancer. We hypothesized that AXL contributes to the metastasizing potential of non-NMA NBL and tested if AXL silencing diminishes malignant properties of high AXL expressing cell lines. AXL was silenced in two non-NMA NBL cell lines by using a lentiviral shRNA construct that was able to transduce these cell lines with >90% infection efficiency. AXL mRNA expression level was efficiently knocked-down resulting in a severe decrease of migration of AXL positive cell lines GI-M-EN and SH-EP-2, and decreased invasion of GI-M-EN. Morphologically, AXL knockdown induced more rounded cells with a loss of contact. Intracellularly, we observed induction of stress fibers (immunofluorescence F-actin) in GI-M-EN. These changes in cytoskelet were associated with decreased migration. No effects were observed for cell proliferation, apoptosis or downstream pathways. In conclusion, AXL is identified as a possible mediator of NBL metastasis. Arrays were performed with 5 different PNET cell lines, which were used as controls for 17 NBL cell lines (GSE22771)
- Species:
- human
- Samples:
- 22
- Source:
- E-GEOD-33903
- Updated:
- Dec.12, 2014
- Registered:
- Sep.16, 2014
Sample | ALK MUTATION STATUS | GENDER | CELL TYPE | MYCN STATUS |
---|---|---|---|---|
GSM563179 | wild type | female | neuroblastoma cell line | no MYCN amplification |
GSM563180 | mutated | male | neuroblastoma cell line | no MYCN amplification |
GSM563179 | wild type | female | neuroblastoma cell line | no MYCN amplification |
GSM563182 | wild type | male | neuroblastoma cell line | MYCN amplified |
GSM563183 | mutated | male | neuroblastoma cell line | MYCN amplified |
GSM563183 | mutated | male | neuroblastoma cell line | MYCN amplified |
GSM563185 | mutated | female | neuroblastoma cell line | MYCN amplified |
GSM563182 | wild type | male | neuroblastoma cell line | MYCN amplified |
GSM563187 | amplified | female | neuroblastoma cell line | MYCN amplified |
GSM563188 | mutated | female | derivative of neuroblastoma cell line NBL16 | no MYCN amplification |
GSM563188 | mutated | female | derivative of neuroblastoma cell line NBL16 | no MYCN amplification |
GSM563190 | wild type | male | neuroblastoma cell line | no MYCN amplification |
GSM56319 | wild type | female | neuroblastoma cell line | MYCN amplified |
GSM563182 | wild type | male | neuroblastoma cell line | MYCN amplified |
GSM563187 | amplified | female | neuroblastoma cell line | MYCN amplified |
GSM563194 | mutated | female | neuroblastoma cell line | no MYCN amplification |
GSM563187 | amplified | female | neuroblastoma cell line | MYCN amplified |
GSM838617 | not specified | female | not specified | not specified |
GSM838617 | not specified | female | not specified | not specified |
GSM838617 | not specified | female | not specified | not specified |
GSM838617 | not specified | female | not specified | not specified |
GSM838617 | not specified | female | not specified | not specified |